If you have been reading about Fragment designation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Some GLP-1 agonists, such as tirzepatide, are also agonists of the GIP receptor, glucagon receptor, and/or amylin receptor. These additional targets are hoped to increase the amount of weight loss the drugs cause.
Off-line is an older method than on-line and involves the chemical analysis of sampled aerosols collected traditionally on filters or with cascade impactors (shown to the right) in the field and analyzed back in the lab. Cascade impactors collects particles as they transverse a series of impaction plates, and separate them based on size. The aerosol samples are analyzed by the coupling of pre-separation methods with mass spectrometry. The benefit of this method relative to on-line sampling is greater molecular and structural speciation. The greater molecular and structural speciation is due to the pre-separation. There are many different types of instrumentation used for the analysis due to various type and combinations of the ionization, separation, and mass detection methods. Not one combination is best for all samples, and as such depending on the need for analysis, different instrumentation is used. The most commonly used ionization method for off-line instrument is electron ionization (EI) which is a hard ionization technique that utilized 70 eV to ionize the sample, which causes significant fragmentation that can be used in a library search to identify the compounds. The separation method that EI is usually coupled with is gas chromatography (GC), where in GC the particles are separated by their boiling points and polarity, followed by solvent extraction of the samples collected on the filters.
== Technology == Flagler Global Logistics is using a new, proprietary, single-source, cold chain technology to attract more business from Latin and South American importers of perishable goods. Importers generally use colder northern ports, and then truck the products (which can include fruits, vegetables, and fresh-cut flowers) south in order to protect local farms against fruit flies and other pests. However, this circuitous supply chain route can contribute to large losses in products. Industry reports estimate that $35 billion in perishable foods are lost annually between farm and table, with nearly half of those losses due to in-transit temperature changes. FGL's new facility allows the company to employ a new cold chain process and treatment methods that can extend the shelf life of produce and other perishable items. In December 2013, the USDA approved the Logistics Center's treatment methods. Flagler Global Logistics President and CEO Chris Scott described the USDA approval as a “game-changer” in the industry, because it opens up Miami as a viable alternate distribution hub for Latin America exporters. Flagler Global Logistics also holds certifications from PrimusGFS (Global Food Safety Initiative scheme) and the FDA.
Sources: en.wikipedia.org
The hypothalamic–pituitary–somatotropic axis (HPS axis), or hypothalamic–pituitary–somatic axis, also known as the hypothalamic–pituitary–growth axis, is a hypothalamic–pituitary axis which includes the secretion of growth hormone (GH; somatotropin) from the somatotropes of the pituitary gland into the circulation and the subsequent stimulation of insulin-like growth factor 1 (IGF-1; somatomedin-1) production by GH in tissues such as, namely, the liver. Other hypothalamic–pituitary hormones such as growth hormone-releasing hormone (GHRH; somatocrinin), growth hormone-inhibiting hormone (GHIH; somatostatin), and ghrelin (GHS) are involved in the control of GH secretion from the pituitary gland. The HPS axis is involved in postnatal human growth. Individuals with growth hormone deficiency or Laron syndrome (GHRTooltip growth hormone receptor insensitivity) show symptoms like short stature, dwarfism and obesity, but are also protected from some forms of cancer. Conversely, acromegaly and gigantism are conditions of GH and IGF-1 excess usually due to a pituitary tumor, and are characterized by overgrowth and tall stature.
For example, the energetics of the covalent bond to the serine molecule in chymotrypsin should be compared to the well-understood covalent bond to the nucleophile in the uncatalyzed solution reaction. A true proposal of a covalent catalysis (where the barrier is lower than the corresponding barrier in solution) would require, for example, a partial covalent bond to the transition state by an enzyme group (e.g., a very strong hydrogen bond), and such effects do not contribute significantly to catalysis.
Le Havre experienced a population boom in the second half of the 19th century. Subsequently, the population drain of the First World War was offset by the annexation of the town of Graville (the city gained 27,215 people between 1911 and 1921). During the Second World War the population decreased significantly (a loss of 57,149 people between 1936 and 1946) because of the exodus and bombings. After the war the commune saw its population increase until 1975. Since then population has decreased again, especially between 1975 and 1982: during these years of industrial crisis the population fell by 18,494 people. The trend continued in the 1980s although at a slower pace. The current policy of the municipality is to build new housing to attract new residents with the goal of exceeding 200,000 inhabitants, a level that was reached in the 1960s. The population of the commune of Le Havre was 191,000 inhabitants in 1999 which placed the city at 12th place among the most populated cities in France and in the first place in Normandy. In 2022 INSEE counted 166,462 people living in the commune of Le Havre, while the urban area of Le Havre had 232,052 inhabitants and the metropolitan area of Le Havre had 335,499 inhabitants.
== Specific examples == Using the bacterial one-hybrid system, one study has characterized 35 members of the Drosophila melanogaster segmentation network which includes representative members of all the major classes of DNA-binding domain proteins. Implications for medical research are evident from another study that used the B1H system to identify the DNA-binding specificity of a transcriptional regulator for a gene in Mycobacterium tuberculosis. The B1H system has also been used to identify an important turnover element in Escherichia coli.
Sources: en.wikipedia.org
are calculated for a short time frame, and the matrices for longer periods of time are calculated by assuming mutations follow a Markov chain model. The base unit of time for the PAM matrices is the time required for 1 mutation to occur per 100 amino acids, sometimes called 'a PAM unit' or 'a PAM' of time. This is precisely the duration of mutation assumed by the PAM1 matrix. The constant
Cyclodextrins were called "cellulosine" when first described by A. Villiers in 1891. Soon after, F. Schardinger identified the three naturally occurring cyclodextrins: α, β, and γ, referred to as "Schardinger sugars". For 25 years, between 1911 and 1935, Hans Pringsheim in Germany was the leading researcher in this area, demonstrating that cyclodextrins formed stable aqueous complexes with many other chemicals. By the mid-1970s, each of the natural cyclodextrins had been structurally and chemically characterized and many more complexes had been studied. Since the 1970s, extensive work has been conducted by Szejtli and others exploring encapsulation by cyclodextrins and their derivatives for industrial and pharmacologic applications. Among the processes used for complexation, the kneading process seems to be one of the best.
== Research == Thymosin α1 (TA1), a molecule with immune enhancing properties, was the first of the thymosins to enter clinical trials. It has been approved in China and more than 30 other countries, and has shown great promise in the treatment of severe sepsis, cancer, and a number of other diseases including the potential treatment of cystic fibrosis. Most recently, TA1 has been found to synergize with a check-point inhibitor and further extend the survival of Stage III/IV melanoma patients previously treated with TA1. Thymosin β4 (Tβ4), the second of the thymosins to reach the clinic, has been shown to accelerate wound healing and the remodeling of injured tissues. An injectable form of Tβ4 has been developed for internal indications such as myocardial infarction, stroke and brain trauma. Early Phase 2 trials have been completed in patients with pressure and venostasis ulcers. Two Phase 2/3 trials in patients with dry eye and neurotrophic keratopathy have been completed in the United States with promising results. A third Phase 3 trial in dry eye will begin in 2019. RegeneRx Biopharmaceuticals is developing an injectable form of Tβ4 for internal indications such as myocardial infarction, stroke, multiple sclerosis, brain trauma, and peripheral neuropathy. Dr. Goldstein's research has helped define the role of biological response modifiers in health and disease, and has led to the discovery of important new links between the immune system, the neuroendocrine system and the brain.
EF-G (elongation factor G, historically known as translocase) is a prokaryotic elongation factor involved in mRNA translation. As a GTPase, EF-G catalyzes the movement (translocation) of transfer RNA (tRNA) and messenger RNA (mRNA) through the ribosome.
Dunkin' Donuts LLC, doing business as Dunkin', is an American multinational fast food restaurant chain specializing in coffee and doughnuts. It was founded by Bill Rosenberg in Quincy, Massachusetts, in 1950. The chain was acquired by Baskin-Robbins' holding company Allied Lyons in 1990. Its acquisition of the Mister Donut chain and the conversion of that chain to Dunkin' Donuts facilitated the brand's growth in North America the same year. Dunkin' and Baskin-Robbins eventually became subsidiaries of Dunkin' Brands, headquartered in Canton, Massachusetts, in 2004. Dunkin' Brands was purchased by Inspire Brands on December 15, 2020. The chain began rebranding as a "beverage-led company", and was renamed Dunkin' in January 2019. While stores in the U.S. began using the new name, the company intends to roll out the rebranding to all of its international locations. With approximately 14,200 locations in 39 countries and $14.5 billion in system sales, Dunkin' is one of the largest coffee shop and doughnut shop chains in the world. In addition to several varieties of coffee and doughnuts, products sold include bagels, breakfast sandwiches, muffins, and doughnut holes branded as Munchkins.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.